Korio
Founded 2021 · 36 employees on LinkedIn · 1 known investors
Korio provides RTSM (Randomization and Trial Supply Management) software designed for clinical trial management across the full trial lifecycle, from kickoff through closeout. The platform serves clinical trial sponsors and research organizations by combining configurable protocol-change management with expert operational guidance.
Also known as Korio, Inc.
Investors · 1
Company profile
researched Aug 2026Korio, Inc. develops Randomization and Trial Supply Management (RTSM), also referred to as IRT, software for clinical trials. The platform is designed to support studies across the full lifecycle, from rapid study startup through kickoff, protocol amendments and study closeout. Core capabilities described by the company include a configurable system that absorbs protocol changes, reusable validated components, automated testing, a streamlined configuration model, and role-based dashboards giving real-time visibility into subject activity, investigational product supply and system health, with proactive monitoring to flag issues.
The company positions itself as focused exclusively on RTSM rather than offering a broader all-in-one eClinical suite. Alongside the software, Korio provides continuity of staffing: experienced RTSM project managers remain with a study from kickoff to closeout and have direct access to the platform's configuration tools so changes can be implemented without separate engineering work. Sponsors are also given direct access to the founder-led leadership team. Korio has published case studies covering a personalized-medicine oncology trial taken over mid-study, a rare disease biotech replacing manual processes, and a Phase I trial migrating from spreadsheets to RTSM.
Founding story
Korio was co-founded by Ryan Keane (Founder and CEO) and Chuck Harris (Founder and COO), both of whom previously worked at clinical trial technology provider Endpoint Clinical. Keane spent roughly 15 years in life sciences, beginning as a biostatistician at CRO Pacific Data Designs after an MS in Biostatistics, then ten years at Endpoint Clinical where he rose from business development to Vice President, Business Development and ultimately Chief Commercial Officer. Harris began in regulatory work at the FDA in Boston, moved through consumer technology roles at Excite and Intuit, and then spent two decades in clinical trial technology leadership in San Francisco, most recently as CEO of Endpoint Clinical. He describes co-founding Korio as an opportunity to build an evolved clinical trials platform from a blank canvas. The name Korio is derived from the word "chorus."
Business model
Korio sells RTSM/IRT software to clinical trial sponsors, bundled with expert client services including dedicated project managers who remain assigned to a study for its duration and who configure the system directly.
Traction
The company reported a surge in customer adoption over the year preceding its September 2024 Series A, and publishes case studies including a mid-trial RTSM takeover for a personalized medicine oncology study, a rare disease biotech and a live Phase I trial.
Latest developments
In September 2024 Korio closed a Series A round led by BIP Ventures with participation from Excelerate Health Ventures, Boston Millennia Partners and other strategic investors, earmarked for global expansion and its client services and support organization. During 2025 the company added Matt Bolinski as SVP, Finance and Arvita Tripati as Vice President, Product & Compliance, and continued publishing RTSM articles, webinars and case studies.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Korio describes the RTSM market as split between service-led providers, which are flexible but dependent on people and therefore less predictable in cost and timeline, and product-led providers, which are consistent and fast but rigid when studies change. Korio positions its offering as combining both, and as being 100% focused on RTSM rather than embedding it in an all-in-one suite. BIP Ventures characterized the investment as addressing legacy solutions that struggle with growing study-design complexity, delays, quality concerns and excessive costs.
Stated differentiators include a configuration model that allows mid-study protocol changes without change orders or engineering projects, continuity of the same experienced project team from kickoff to closeout, direct access to founder-led senior leadership, reusability of validated components, and exclusive focus on RTSM.
Technology
A configurable RTSM/IRT platform built around reusable validated components, automated testing and a streamlined configuration model so protocol amendments can be implemented without custom engineering. It provides role-based, role-specific workflows and dashboards covering subject activity, investigational product supply and system health, audit trail and cross-portfolio data surfacing, integration-disruption flagging, and in-application live chat support.
Go-to-market
Direct sales supported by expert consultations, platform demos and demo scheduling, plus a content resource center of articles, webinars, case studies and video platform demos. The CEO stated that growth to date had been fueled by word of mouth from existing customers.
Clinical trial sponsors, including small and mid-sized biotechs and rare disease and oncology developers, plus clinical operations teams at sponsor organizations; customer quotations cite roles such as Head of Clinical Operations and Senior/Associate Director, Clinical Operations.
Geography
Headquartered at 320 E State St, Doylestown, Pennsylvania, USA. The company recruits internationally and stated that Series A proceeds would fund continued global expansion, particularly of its client services and support team.
History
The company raised initial seed funding in September 2023 and completed a Series A round announced on 10 September 2024, led by BIP Ventures with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners and other strategic investors. Korio reported a surge in customer adoption in the year between the two rounds, with growth described as driven largely by customer word of mouth. Leadership hires reported in 2025 include Matt Bolinski as SVP, Finance and Arvita Tripati as Vice President, Product & Compliance.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsKorio, Inc. announced completion of a Series A funding round led by BIP Ventures, with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners and other strategic investors. Proceeds are earmarked for global expansion and the client services and support team.
Korio completed its initial seed funding round in September 2023, a year before its Series A.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Koriokorioclinical.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Korio do?
- Korio is a clinical trial software company providing a configurable RTSM/IRT platform with expert-led study support services.
- Who are Korio's investors?
- Korio's investors include Excelerate Health Ventures.